Table 3.
Frequency of Adverse Events
| Adverse Events | Sorafenib | Lenvatinib | Atez/Bev | |||
|---|---|---|---|---|---|---|
| (N=118) | (N=21) | (N=38) | ||||
| Grade ≥3 | Any Grade | Grade ≥3 | Any Grade | Grade ≥3 | Any Grade | |
| Number (Percent) | ||||||
| Pulmonary embolism | 0 | 0 | 2 (9.5%) | 2 (9.5%) | 0 | 0 |
| Hypertension | 3 (2.5%) | 3 (2.5%) | 0 | 6 (28.6%) | 0 | 2 (5.3%) |
| Fatigue | 22 (18.6%) | 26 (22%) | 1 (4.8%) | 11 (52.4%) | 0 | 1 (2.6%) |
| Dyspnea | 11 (9.3%) | 11 (9.3%) | 0 | 1 (4.8%) | 0 | 1 (2.6%) |
| Rash/Pruritus | 10 (8.5%) | 10 (8.5%) | 0 | 1 (4.8%) | 0 | 1 (2.6%) |
| Mucositis | 5 (4.2%) | 5 (4.2%) | 1 (4.8%) | 4 (19%) | 0 | 0 |
| Colitis | 0 | 0 | 0 | 0 | 2 (5.3%) | 2 (5.3%) |
| Cardiotoxicity | 1 (0.8%) | 1 (0.8%) | 0 | 1 (4.8%) | 1 (2.6%) | 1 (2.6%) |
| Diarrhea | 12 (10.2%) | 15 (12.7%) | 1 (4.8%) | 4 (19%) | 0 | 0 |
| Anemia | 9 (7.6%) | 9 (7.6%) | 0 | 0 | 0 | 5 (13.2%) |
| Hand-Feet-Syndrome | 13 (11%) | 14 (11.9%) | 0 | 0 | 0 | 0 |
| INR elevation | 0 | 0 | 1 (4.8%) | 1 (4.8%) | 0 | 0 |
| Nausea/Emesis | 21 (17.8%) | 24 (20.3%) | 0 | 2 (9.5%) | 2 (5.3%) | 2 (5.3%) |
| irAE | 0 | 0 | 0 | 0 | 2 (5.3%) | 2 (5.3%) |
| Weight/appetite loss | 6 (5.1%) | 8 (6.8%) | 0 | 7 (33.3%) | 0 | 0 |
| Proteinuria | 0 | 0 | 0 | 2 (9.5%) | 1 (2.6%) | 1 (2.6%) |
| GIT-Bleeding | 3 (2.5%) | 3 (2.5%) | 0 | 1 (4.8%) | 1 (2.6%) | 1 (2.6%) |
| Nosebleeds | 1 (0.8%) | 1 (0.8%) | 0 | 0 | 0 | 0 |
| Keratosis | 1 (0.8%) | 1 (0.8%) | 0 | 0 | 0 | 0 |
Notes: We summarized urinary tract infections, pneumonias, fever and all other infections as infections; encephalopathia, dizziness, tremor, epileptic attacks and paresthesias as neurological AEs (Data are presented as absolute frequency with relative frequency in parenthesis.).
Abbreviations: Ire AE, Immune related adverse events; GIT-Bleeding, gastrointestinal bleeding.